Incorporation of environmental factors into outcomes research.

Abstract:

:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying health, disability and handicap, conceptualizing intervention and assessing outcome. This framework, the International Classification of Functioning, Disability and Health (ICF), is now defined by its recognition of the impact of environmental and personal factors on body function and structure, activities and participation in disablement. The ICF offers the potential to advance the understanding and integration of environmental dimensions into outcome research and measurement in health and disability. This paper proposes that a key future challenge for outcomes research is to understand and document environmental dimensions of health and disability using the precedent of the ICF. Potential steps and obstacles to this development are suggested, and the direct practice and broader policy applications gained by linking an international conceptual framework with clinical outcome research and practice are discussed.

authors

Kuipers P,Foster MM,Bellamy N

doi

10.1586/14737167.3.2.125

subject

Has Abstract

pub_date

2003-04-01 00:00:00

pages

125-9

issue

2

eissn

1473-7167

issn

1744-8379

journal_volume

3

pub_type

杂志文章
  • Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.

    abstract::The aim of this systematic review was to collect all current data on indirect costs related to inflammatory bowel disease as well as assessing homogeneity and comparability, and conducting a meta-analysis. Costs were collected using databases from Medline, Embase and Centre for Reviews and Dissemination databases, the...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737167.2015.1011130

    authors: Kawalec P,Malinowski KP

    更新日期:2015-04-01 00:00:00

  • Quality of care for Medicare beneficiaries with disabilities under the age of 65 years.

    abstract::Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.3.261

    authors: Iezzoni LI

    更新日期:2006-06-01 00:00:00

  • Cost-effectiveness of palivizumab in infancy.

    abstract::Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.5.445

    authors: Embleton ND,Dharmaraj ST,Deshpande S

    更新日期:2007-10-01 00:00:00

  • When a parent has cancer: challenges to patients, their families and health providers.

    abstract::At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.12.62

    authors: Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

    更新日期:2012-12-01 00:00:00

  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis.

    abstract:AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.4.337

    authors: Roger A,Fortea J,Mora S,Artés M

    更新日期:2008-08-01 00:00:00

  • A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.

    abstract::We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2013.838027

    authors: Neumann PJ,Saret CJ

    更新日期:2013-10-01 00:00:00

  • Non-communicating children's pain checklist: better pain assessment for severely disabled children.

    abstract::Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.3.327

    authors: Breau LM

    更新日期:2003-06-01 00:00:00

  • Threshold denial rates in prior authorization prescription programs.

    abstract::In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.2.165

    authors: Grant WC,Yoder DM,Mullins CD

    更新日期:2004-04-01 00:00:00

  • Price comparison of high-cost originator medicines in European countries.

    abstract:BACKGROUND:In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-incom...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2016.1223543

    authors: Vogler S,Zimmermann N,Babar ZU

    更新日期:2017-04-01 00:00:00

  • Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

    abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1476142

    authors: Grewal S,Ramsey S,Balu S,Carlson JJ

    更新日期:2018-08-01 00:00:00

  • The German method for setting ceiling prices for drugs: in some cases less data are required.

    abstract::The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.11.45

    authors: Gandjour A,Gafni A

    更新日期:2011-08-01 00:00:00

  • Patient-reported treatment satisfaction measures for long-term anticoagulant therapy.

    abstract::A comprehensive literature search identified seven instruments, of which three had psychometric data available. These were the 'Sawicki instrument', the Duke Anticoagulation Satisfaction Scale (DASS) and Deep Vein Thrombosis Quality of Life (DVTQoL). Sawicki assessed five domains with acceptable internal reliability. ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.3.291

    authors: Wild D,Murray M,Shakespeare A,Reaney M,von Maltzahn R

    更新日期:2008-06-01 00:00:00

  • The Cancer Outcomes Measurement Working Group: rationale overview and a look to the future.

    abstract::In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.4.407

    authors: Snyder C,Gotay CC,Lipscomb J

    更新日期:2006-08-01 00:00:00

  • Nursing home costs and quality of care: is there a tradeoff?

    abstract::Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.1.99

    authors: Weech-Maldonado R,Mor V,Oluwole A

    更新日期:2004-02-01 00:00:00

  • Quality-of-life concerns in lung cancer patients.

    abstract::Lung cancer is a leading cause of cancer deaths for both men and women across the world. In the past, studies on lung cancer have focused on traditional end points such as survival, disease-free survival or local control. More recently, investigators have begun to appreciate the importance of health-related quality-of...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.81

    authors: Siddiqui F,Konski AA,Movsas B

    更新日期:2010-12-01 00:00:00

  • Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials.

    abstract::The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.57

    authors: Hamidou Z,Dabakuyo TS,Bonnetain F

    更新日期:2011-10-01 00:00:00

  • Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.

    abstract::Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical tr...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.3.227

    authors: Wade WE,Spruill WJ

    更新日期:2007-06-01 00:00:00

  • Person tradeoffs and the problem of risk.

    abstract::Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.6.677

    authors: Doctor JN,Miyamoto JM

    更新日期:2005-12-01 00:00:00

  • Black or white cat? Ideology meets reality in healthcare finance and provision.

    abstract::Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.6.647

    authors: Lim MK

    更新日期:2006-12-01 00:00:00

  • Role of patient and public participation in health technology assessment and coverage decisions.

    abstract::Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.82

    authors: Menon D,Stafinski T

    更新日期:2011-02-01 00:00:00

  • Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS.

    abstract::There have been great technological advances in the use of antiretroviral therapies to slow down disease progression in HIV/AIDS. Combinations of therapeutics and the use of several diagnostic methods have resulted in both declines in mortality and the occurrence of opportunistic infections. The higher costs of these ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.1.1.77

    authors: Bos JM,Berg LT,Postma MJ

    更新日期:2001-10-01 00:00:00

  • Update on the use of osteoarthritis-specific outcome measures.

    abstract::Osteoarthritis is the single most important cause of disability and limitation of activity of elderly people in the UK. Although joint replacement is now commonplace for hips and increasingly so for knees, pharmacological management continues to be important. In this context, it is necessary to identify valid and acce...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2.4.337

    authors: Walters SJ,Lloyd-Jones M

    更新日期:2002-08-01 00:00:00

  • Antibiotics and reduced risk of COPD re-exacerbations.

    abstract::Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.33

    authors: Antoniu SA

    更新日期:2009-08-01 00:00:00

  • HRQOL and subjective well-being: noncomplementary forms of outcome measurement.

    abstract::This review considers some of the broad principles that concern quality of life assessment. These are discussed in relation to health-related quality of life (HRQOL) and the measurement of subjective well-being. It is argued that there are serious logical and methodological issues concerning HRQOL measurement, to the ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.4.413

    authors: Cummins RA,Lau AL,Stokes M

    更新日期:2004-08-01 00:00:00

  • A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.

    abstract::Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.13.26

    authors: Garg V,Gu NY,Borrego ME,Raisch DW

    更新日期:2013-06-01 00:00:00

  • Costs of multiple sclerosis - extrapolation of Czech data to Polish patients.

    abstract:AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2014.906305

    authors: Szmurło D,Fundament T,Ziobro M,Kruntorádová K,Doležal T,Głogowski C

    更新日期:2014-06-01 00:00:00

  • Priority setting in healthcare: towards guidelines for the program budgeting and marginal analysis framework.

    abstract::Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.66

    authors: Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

    更新日期:2010-10-01 00:00:00

  • Better big data.

    abstract::By 2018, Medicare payments will be tied to quality of care. The Centers for Medicare and Medicaid Services currently use quality-based metric for some reimbursements through their different programs. Existing and future quality metrics will rely on risk adjustment to avoid unfairly punishing those who see the sickest,...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 社论

    doi:10.1586/14737167.2015.1083864

    authors: Al Kazzi ES,Hutfless S

    更新日期:2015-01-01 00:00:00

  • Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban.

    abstract::This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.1.49

    authors: Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

    更新日期:2007-02-01 00:00:00